Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Abituzumab × Gastrointestinal × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Oxaliplatin 770 Fluorouracil 633 Capecitabine 566 Gemcitabine 474 Leucovorin 453 Irinotecan 444 Bevacizumab 439 Cisplatin 333 Radiotherapy 278 Cetuximab 251 Paclitaxel 179 pembrolizumab 173 S 1 (combination) 173 Docetaxel 156 Nivolumab 144 Drug Therapy 144 sintilimab 140 apatinib 129 tislelizumab 128 130-nm albumin-bound paclitaxel 125 durvalumab 119 Folfox protocol 116 Albumin-Bound Paclitaxel 116 camrelizumab 107 Panitumumab 106 lenvatinib 105 Surgical Procedures, Operative 102 regorafenib 100 Sorafenib 99 Radiation 87

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03688230 2020-03-18

AMELION

SFJ Pharmaceuticals, Inc.

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡